Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Cardiovascular

Tevard presents suptRNA data in DMD and dilated cardiomyopathy

Sep. 30, 2025

Tevard Biosciences Inc. has presented new preclinical data on the use of therapeutic suppressor tRNAs (suptRNAs) for the treatment of Duchenne muscular dystrophy (DMD) and dilated cardiomyopathy (DCM). The data show potent restoration of full-length functional proteins in models of DMD and DCM caused by titin truncations (DCM-TTNtv).

Neurology/psychiatric

Hager Biosciences discloses new antagonists of orexin and κ-opioid receptors

Sep. 26, 2025

Hager Biosciences LLC has identified orexin receptor and/or κ-opioid receptor dual antagonists reported to be useful for the treatment of cancer, psychiatric, neurological and cardiovascular disorders.

Neurology/psychiatric

VHB-937 drives microglial activation to promote neuroprotection in the CNS

Sep. 26, 2025

No Comments

Researchers from Novartis AG reported preclinical efficacy data on VHB-937, an agonist human monoclonal antibody targeting TREM2 in models of neuroinflammation.

Silhouette of head and brain with DNA double helixes

Neurology/psychiatric

Youthbio gains FDA feedback for Alzheimer’s gene therapy YB-002

Sep. 26, 2025

No Comments

Youthbio Therapeutics Inc. has held a successful INTERACT meeting with the FDA for its lead Alzheimer’s candidate, YB-002.

Neurology/psychiatric

Cellular senescence may trigger MS progression

Sep. 26, 2025

By Xavier Bofill Bruna

No Comments

Is there a link between cellular senescence and multiple sclerosis (MS) progression? Several presentations at this year’s European Committee for Treatment and Research in Multiple Sclerosis 2025 (ECTRIMS 2025) conference, which ends today in Barcelona, addressed this question.

Neurology/psychiatric

Neushen Therapeutics synthesizes new NLRP3 inflammasome inhibitors

Sep. 25, 2025

Neushen Therapeutics Inc. has patented NLRP3 inflammasome inhibitors reported to be useful for the treatment of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis and Huntington’s disease.

Neurology/psychiatric

Cure Rare Disease’s CRD-003 designated orphan drug for LGMD2i/R9

Sep. 25, 2025

No Comments

The FDA has awarded orphan drug designation to Cure Rare Disease’s CRD-003 for the treatment of limb-girdle muscular dystrophy type R9 (LGMD2i/R9), a congenital muscular dystrophy caused by biallelic mutations in the FKRP gene.

Neurology/psychiatric

UK college offers guidance, clarity for psychedelic research

Sep. 23, 2025

By Nuala Moran

No Comments

The Royal College of Psychiatrists in the U.K. has published its first-ever guidance to support research into psychedelic drugs as therapies for conditions including treatment-resistant depression, substance abuse disorders and posttraumatic stress disorder, saying that in a fast-moving field there is a risk of jumping ahead of the evidence.

Neurology/psychiatric

Humanwell Healthcare describes new P2RX7 antagonists

Sep. 23, 2025

Humanwell Healthcare (Group) Co. Ltd. has divulged P2X purinoceptor 7 (P2RX7; P2X7) antagonists reported to be useful for the treatment of pain, inflammatory, neurological and immunological disorders.

Neurology/psychiatric

Miralogx and Mira Pharmaceuticals report MAO-A/MAO-B inhibitors

Sep. 22, 2025

Miralogx LLC and Mira Pharmaceuticals Inc. have jointly disclosed new cannabinoid analogues acting as monoamine oxidase-A (MAO-A) and/or MAO-B inhibitors reported to be useful for the treatment of epilepsy, anxiety disorders and pain.

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

BioWorld Science, Neurology/psychiatric RSS

BioWorld Science, Neurology/psychiatric
RSS